Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 6:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Infection Resistant to Drugs Clear all
Recruiting Phase 1 Interventional

Fecal Microbiota Transplantation as a Strategy to Eradicate Resistant Organisms

NCT02543866
View directory record Official record
Conditions
Infection Resistant to Drugs
Interventions
Fecal Microbiota Transplantation
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
7 Years to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Sep 28, 2026, 6:09 PM EDT
Completed Not applicable Interventional Results available

Active Bathing to Eliminate Infection (ABATE Infection) Trial

NCT02063867
View directory record Official record
Conditions
Healthcare Associated Infections, Methicillin Resistant Staphylococcus Aureus, Multi Drug Resistant Organisms
Interventions
Arm 2: Decolonization
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
12 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
52
States / cities
West Hills, California • Thornton, Colorado • Bradenton, Florida + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Sep 28, 2026, 6:09 PM EDT
Completed Not applicable Interventional

A Study to Evaluate the Effects of Azithromycin on MAC Disease Prevention in HIV-Positive Patients

NCT00000947
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Azithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
19
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 28, 2026, 6:09 PM EDT
Terminated Phase 4 Interventional

Testing the Safety and Efficacy of Commercial Drug Biktarvy in Subjects Known to Have the 184 Resistance Mutation to a Component in Biktarvy

NCT04040075
View directory record Official record
Conditions
HIV-1-infection
Interventions
Biktarvy Tab
Drug
Lead sponsor
Southampton Healthcare, Inc.
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Sep 28, 2026, 6:09 PM EDT
Terminated Phase 4 Interventional Results available

Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV

NCT01443923
View directory record Official record
Conditions
Hepatitis, HIV/AIDS
Interventions
Boceprevir, Peg-Interferon-alfa 2B, Ribavirin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2015 · Synced Sep 28, 2026, 6:09 PM EDT
Completed Not applicable Interventional

A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3

NCT00000859
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Nelfinavir mesylate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
32
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 28, 2026, 6:09 PM EDT
Withdrawn Phase 3 Interventional

Salvage Treatment, Resistance Testing, and Withdrawal of Anti-HIV Drugs for HIV Patients Failing Current Anti-HIV Treatment

NCT00011128
View directory record Official record
Conditions
HIV Infections
Interventions
Antiretroviral Treatment Interruption
Behavioral
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 17, 2015 · Synced Sep 28, 2026, 6:09 PM EDT
Completed No phase listed Observational

Multi-Drug Resistant Organism Network

NCT03646227
View directory record Official record
Conditions
Infections Resistant to Multiple Drugs, Bacterial Infections
Interventions
Standard of Care
Other
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
6,496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2023 · Synced Sep 28, 2026, 6:09 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

NCT02362503
View directory record Official record
Conditions
HIV Infections
Interventions
BMS-663068, Placebo
Drug · Other
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
39
States / cities
Los Angeles, California • Palm Springs, California • San Francisco, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 28, 2026, 6:09 PM EDT
Completed Phase 3 Interventional

A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients

NCT00002410
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Zidovudine
Drug
Lead sponsor
Dupont Merck
Industry
Eligibility
13 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 28, 2026, 6:09 PM EDT
Completed Not applicable Interventional Results available

Smartphone Based aDOT Treatment With Fixed-Dose Elbasvir and Grazoprevir in PWIDs

NCT03127358
View directory record Official record
Conditions
Hepatitis C, Medication Adherence
Interventions
AiCure, AiCure with gamification
Device
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Sep 28, 2026, 6:09 PM EDT
Completed Not applicable Interventional

Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus

NCT02098616
View directory record Official record
Conditions
Hepatitis C
Interventions
DCV/ASV/BMS-791325, DCV/ASV/BMS-791325 + RBV
Drug
Lead sponsor
Timothy Morgan, MD
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Sep 28, 2026, 6:09 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Biology of HIV Transmission

NCT00001092
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2008
U.S. locations
3
States / cities
Los Angeles, California • San Diego, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2015 · Synced Sep 28, 2026, 6:09 PM EDT
Terminated Phase 2Phase 3 Interventional

Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection

NCT00612898
View directory record Official record
Conditions
HIV Infections
Interventions
apricitabine, lamivudine
Drug
Lead sponsor
Avexa
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2012 · Synced Sep 28, 2026, 6:09 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Pilot Study Assessing Intestinal Microbiota Diversification and Changes After Travel to South(East) Asia From the US

NCT03043300
View directory record Official record
Conditions
Dysbiosis
Interventions
Screening Criteria Review, Pre-Travel Questionnaire, Pre-Travel Stool Specimen Collection, Short-Term Post-Travel Questionnaire, Short-Term Post-Travel Stool Specimen Collection, Long-Term Post-Travel Questionnaire, Long-Term Post-Travel Stool Specimen Collection
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Sep 28, 2026, 6:09 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria

NCT03580044
View directory record Official record
Conditions
Serious Bacterial Infection
Interventions
ATM-AVI, BAT
Combination Product · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Sep 28, 2026, 6:09 PM EDT
Completed Phase 3 Interventional

New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)

NCT00035854
View directory record Official record
Conditions
Bacterial Infections
Interventions
Zyvox® / Linezolid
Drug
Lead sponsor
Pfizer
Industry
Eligibility
Up to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
21
States / cities
Long Beach, California • Los Angeles, California • Hartford, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2009 · Synced Sep 28, 2026, 6:09 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class Antiretroviral Resistance

NCT04648280
View directory record Official record
Conditions
HIV Infections With Multi Drug Resistant Virus
Interventions
Fostemsavir
Drug
Lead sponsor
PENTA Foundation
Network
Eligibility
6 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 28, 2026, 6:09 PM EDT
Completed No phase listed Observational

HIV Resistance and Treatment Strategies

NCT00581802
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Sep 28, 2026, 6:09 PM EDT
Terminated Phase 3 Interventional

Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140

NCT00123890
View directory record Official record
Conditions
HIV Infection
Interventions
GW873140
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
34
States / cities
Tucson, Arizona • Laguna Beach, California • Long Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Sep 28, 2026, 6:09 PM EDT
Completed Phase 2 Interventional

An Open-Label, Pilot Study to Evaluate the Development of Resistance to Nevirapine (BI-RG-587) in HIV-Infected Patients With CD4 Cell Count >= 500/mm3

NCT00000747
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced Sep 28, 2026, 6:09 PM EDT
Completed Phase 1 Interventional

Capravirine to Treat Children With HIV Infection

NCT00006519
View directory record Official record
Conditions
HIV Infection
Interventions
Capravirine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 10, 2006 · Synced Sep 28, 2026, 6:09 PM EDT
Completed No phase listed Observational

Drug Resistance Factors In Healthcare-associated Pneumonia

NCT02736097
View directory record Official record
Conditions
Pneumonia, Critical Illness
Interventions
Not listed
Lead sponsor
Critical Care Pharmacotherapy Trials Network
Other
Eligibility
18 Years to 89 Years
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
29
States / cities
Little Rock, Arkansas • Hartford, Connecticut • Jacksonville, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 28, 2026, 6:09 PM EDT
Recruiting Phase 2 Interventional

Further MT for Antibiotic-Resistant Bacterial Colonization

NCT05835206
View directory record Official record
Conditions
Intestinal Multi-drug Resistant Organism Colonization
Interventions
Microbiome Therapeutic, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Atlanta, Georgia • Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 28, 2026, 6:09 PM EDT